#asco
Latest news and interesting information about asco.
Americans fined for entering Pan the monkey's enclosure in Japan
Two Americans fined in Japan for illegally entering the enclosure of famous monkey Pan. Incident occurred at Ichikawa zoo.
ASCO subsidiary gets interim director
Interim director appointed for ASCO subsidiary 'Denizci Repair-Construction'. Rahim Mikayilov assigned temporarily.
Legend Biotech Buy Rating Reiterated
H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.
Cogent Stock Price Target Raised to $55
Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.
Prostate cancer death risk cut by 20% with J&J drug
Johnson & Johnson's apalutamide reduces prostate cancer death risk by 20%, according to Phase 3 trial results.
Kəpəz extends Verdasco's contract by 2 years
Kəpəz club extends Portuguese defender Diogo Verdasco's contract for 2 years. He played 28 matches and scored 1 goal last season.
Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.
Mexico, EU to sign trade deal Friday
Mexico and the European Union will sign a trade deal on Friday to diversify supply chains and boost investment. Read more on Bond.az.
Mehman Mehdiyev leaves ASCO
Mehman Mehdiyev resigns from ASCO, moving to the State Statistics Committee. He served as press secretary for nearly a decade.
Rentokil Initial Names Rafael Carrasco as North America CEO
Rentokil Initial appoints Rafael Carrasco as CEO for North America, effective August 3. He brings extensive experience in route-based services.
Genentech to Present Breast Cancer Data at ASCO Meeting
Genentech will present breast cancer data on giredestrant and other drugs at the 2026 ASCO meeting.
Revolution stock buy rating from Truist
Truist Securities gives Revolution Medicines a buy rating with a $179 price target. Daraxon's potential and company outlook.
...